565 related articles for article (PubMed ID: 30791783)
1. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
2. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
3. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
4. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
5. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars in inflammatory bowel disease.
Gargallo CJ; Lué A; Gomollón F
Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in inflammatory bowel disease: ready for prime time?
Gomollón F
Curr Opin Gastroenterol; 2015 Jul; 31(4):290-5. PubMed ID: 26039720
[TBL] [Abstract][Full Text] [Related]
9. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
[TBL] [Abstract][Full Text] [Related]
10. The biosimilar road in inflammatory bowel disease: the right way?
Fiorino G; Danese S
Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
[TBL] [Abstract][Full Text] [Related]
11. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
Zheng MK; Shih DQ; Chen GC
World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
[TBL] [Abstract][Full Text] [Related]
14. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.
D'Amico F; Pouillon L; Argollo M; Hart A; Fiorino G; Vegni E; Radice S; Gilardi D; Fazio M; Leone S; Bonovas S; Magro F; Danese S; Peyrin-Biroulet L
Dig Liver Dis; 2020 Feb; 52(2):138-142. PubMed ID: 31812570
[TBL] [Abstract][Full Text] [Related]
16. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
[TBL] [Abstract][Full Text] [Related]
18. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
19. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
20. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
Danese S; Gomollon F;
J Crohns Colitis; 2013 Aug; 7(7):586-9. PubMed ID: 23623738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]